Roche’s Tecentriq Plus Avastin Combination Reduced the Risk of Cancer Returning in People with Certain Types of Early-Stage Liver Cancer in a Phase III Trial
The Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma at high risk of recurrence following surgery met the primary endpoint of recurrence-free survival.
[Mucosal Immunology] Investigators review novel findings on the emerging role of mesenchymal cells in this process using insights gained from lineage tracing approaches, Cre-based genes deletion and single cells transcriptomics.
[Life Science Alliance] Scientists found a higher HCC incidence in methamphetamine (METH) abusers. METH promoted cellular proliferation, migration, and invasion in two human-derived HCC cells.
[Cell Death Discovery] Human hepatoma PLC/PRF/5-ASBT and THP1 cell lines or primary mouse hepatocytes were used for mechanistic studies. Hepatic TNFRSF12A expression was markedly increased in obstructive cholestasis or primary biliary cholangitis patients.